Lakefront Biotherapeutics (GLPGF) Inventory (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Inventory for 14 consecutive years, with $20.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Inventory fell 48.87% year-over-year to $20.7 million in Q1 2026; TTM through Mar 2026 was $20.7 million, a 48.87% decrease from a year earlier, with the FY2025 full-year figure at $25.4 million, down 54.13% from the prior year.
• Inventory was $20.7 million for Q1 2026 at Lakefront Biotherapeutics, down from $26.2 million in the prior quarter.
• Over five years, Inventory peaked at $54.0 billion in Q4 2022 and troughed at $20.6 million in Q1 2022.
• A 5-year average of $4.2 billion and a median of $54.7 million in 2024 frame the typical range for Inventory.
• The widest YoY moves for Inventory: up 169.11% in 2023, down 99.85% in 2023.
• Over 5 years, Inventory stood at $54.0 billion in 2022, then tumbled by 99.85% to $79.6 million in 2023, then tumbled by 31.27% to $54.7 million in 2024, then tumbled by 52.14% to $26.2 million in 2025, then retreated by 20.89% to $20.7 million in 2026.
• The last three Inventory figures came in at $20.7 million (Q1 2026), $26.2 million (Q4 2025), and $26.8 million (Q3 2025), per Business Quant data.